AnticancerPositive observation
Record detail YSL by itself exhibits limited anticancer activity, with an IC50 value of 4.34 mM (Figure S20).
- Measure
- other
- Value
- 4.34 mM
- Target
- MCF-7
- Assay
- Not reported by source
Primary literature evidence
Experimental evidence search
Search paper-level observations with their value, target, assay, evidence sentence, source location, and stable record links. Evidence without a safely standardized sequence remains visible without being misrepresented as a canonical peptide.
Evidence records
5 results
AnticancerPositive observation
Record detail in the presence of 4.0 μM 5F–C12, the anticancer activity of YSL was remarkably potentiated, lowering the IC50 to 0.27 mM, corresponding to an improvement of 16.1-fold.
- Measure
- other
- Value
- 0.27 mM
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail YSL treatment resulted in moderate suppression of approximately 36.4%.
- Measure
- percent_inhibition
- Value
- approximately 36.4%
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail In the YSL (8 mg/kg) + 5F–C12 (0.8 mg/kg) group, tumor inhibition increased markedly, reaching approximately 65.7% (Table S2).
- Measure
- percent_inhibition
- Value
- approximately 65.7%
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail mice treated with YSL (8 mg/kg) combined with a higher dose of 5F–C12 (1.6 mg/kg) exhibited an even more pronounced tumor growth inhibition of 81.1% (Figure 6b,d).
- Measure
- percent_inhibition
- Value
- 81.1%
- Target
- MCF-7
- Assay
- Not reported by source
Names such as P1, PEP1, or peptide 1 are paper-local labels. Search results group them by publication and never assume cross-paper molecular identity without sequence or explicit structural evidence.